Tower Research Capital LLC (Trc) Aligos Therapeutics, Inc. Transaction History

Tower Research Capital LLC (Trc)

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.35 - $1.07 $13,458 - $41,145	38,454 Added 479.36%	46,476 $16,000
Q1 2024 May 15, 2024	SELL	$0.64 - $1.13 $6,851 - $12,097	-10,706 Reduced 57.17%	8,022 $7,000
Q4 2023 Feb 13, 2024	BUY	$0.56 - $0.8 $10,487 - $14,982	18,728 New	18,728 $12,000
Q1 2023 May 09, 2023	BUY	$0.87 - $2.11 $80 - $194	92 New	92 $0
Q3 2022 Nov 10, 2022	SELL	$1.06 - $27.5 $11,211 - $290,867	-10,577 Reduced 56.75%	8,062 $9,000
Q2 2022 Aug 15, 2022	BUY	$1.04 - $2.14 $14,277 - $29,377	13,728 Added 279.54%	18,639 $22,000
Q1 2022 May 12, 2022	BUY	$2.08 - $12.2 $6,154 - $36,099	2,959 Added 151.59%	4,911 $11,000
Q4 2021 Feb 14, 2022	BUY	$11.48 - $17.69 $12,386 - $19,087	1,079 Added 123.6%	1,952 $23,000
Q3 2021 Nov 15, 2021	SELL	$14.57 - $17.72 $8,640 - $10,507	-593 Reduced 40.45%	873 $14,000
Q2 2021 Aug 16, 2021	BUY	$20.3 - $33.6 $13,540 - $22,411	667 Added 83.48%	1,466 $30,000
Q1 2021 May 17, 2021	BUY	$19.1 - $34.94 $5,730 - $10,482	300 Added 60.12%	799 $18,000
Q4 2020 Feb 16, 2021	BUY	$13.2 - $32.74 $6,586 - $16,337	499 New	499 $14,000

253K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.